患者招募：一项比较ALECTINIB与克唑替尼用于治疗初治的ALK阳性晚期非小细胞肺癌的随机、多中心、III期、开放性研究

2015-12-27 MedSci MedSci原创

nitial; background-attachment: initial; background-size: initial; background-origin: initial; background-clip: initial; background-position: initial; background-repeat: initial;">张力中国广东省广州2上海市胸科医院周彩存中

一、题目和背景信息

登记号：	CTR20150592
适应症：	间变性淋巴瘤激酶(ALK)阳性非小细胞肺癌
试验通俗题目：	比较ALECTINIB与克唑替尼用于初治ALK阳性晚期NSCLC的研究
试验专业题目：	一项比较ALECTINIB与克唑替尼用于治疗初治的ALK阳性晚期非小细胞肺癌的随机、多中心、III期、开放性研究
试验方案编号：	BO28984第3版
临床申请受理号：	企业选择不公示
药物名称：	alectinib胶囊
药物类型：	化学药物

二、申办者信息

申办者名称：

1	F.Hoffmann-La Roche Ltd./F.Hoffmann-La Roche Ltd.
2	Excella GmbH/Excella GmbH
3	罗氏（中国）投资有限公司/

联系人姓名：

陈旭

联系人电话：

021-28922888

联系人Email：

jennifer.chen.jc1@roche.com

联系人邮政地址：

广州市中山三路33号中华国际中心B座2201室

联系人邮编：

510055

试验项目经费来源：

完全自筹

三、临床试验信息

1、试验目的

评价和比较alectinib对比克唑替尼在初治的间变性淋巴瘤激酶-阳性非小细胞肺癌患者的疗效、安全性和耐受性。

2、试验设计（单选）

	试验分类：	安全性和有效性
	试验分期：	III期
	设计类型：	平行分组
	随机化：	随机化
	盲法：	开放
	试验范围：	国际多中心试验

3、受试者信息

年龄

18岁(最小年龄)至无岁(最大年龄)

性别

男+女

健康受试者

无

入选标准

1	在组织学上或细胞学上确诊为晚期或复发性（综合治疗无法治愈的IIIB期）或转移性（IV期）且Ventana IHC检查评估为ALK-阳性的NSCLC。需要获得充足的肿瘤组织进行ALK IHC和ALK FISH检查。两种检查均在指定的中心实验室进行。
2	年龄为大于等于18岁
3	预期寿命至少为12周
4	ECOG PS为0-2
5	患者既往未针对晚期或复发（综合治疗无法治愈的IIIB期）或转移性（IV期）NSCLC进行过任何全身治疗。
6	血液功能适当：血小板计数≥100X10^9/L, ANC≥1500 个细胞/μL,血红蛋白≥9.0 g/dL
7	肾功能适当：使用肾病饮食改良公式计算的估计肾小球滤过率（eGFR）至少为45 mL/分钟/1.73 m^2
8	首次使用研究治疗前，患者必须至少已经从所有重大手术或重大创伤的影响中恢复28天
9	进行研究治疗之前有可测量的疾病（根据RECIST v1.1）
10	如果无症状，则在基线时偶然发现的既往脑或脑膜转移是允许的。可对无症状的CNS病变进行治疗，具体由研究者根据本地的临床实践决定。如果患者因CNS转移而存在神经学症状或体征，患者需要完成全脑放疗或伽玛刀治疗。在所有情况下，患者必须在入选前至少14天完成放射治疗，且临床症状稳定。
11	对于所有有生育能力的女性，必须在开始研究治疗前3天内得到妊娠检查阴性结果。
12	对于尚未绝经（非治疗诱导的闭经≥12个月）或未行手术绝育（无卵巢和/或子宫）的女性：同意治疗期间以及使用最后一次研究药物后至少3个月内保持禁欲状态或使用每年的失败率？1%的单一或联合的避孕措施。仅当患者的首选和日常生活方式一致时，禁欲才能够接受。定期禁欲（例如，日历、排卵、症状体温或排卵后法），体外射精并非可接受的避孕措施。每年的失败率< 1%的非激素避孕措施包括输卵管结扎、男性绝育、激素植入、已经确定的口服或注射激素避孕药联合用药的适当应用以及某些宫内避孕器。此外，可以联合使用两种方法（例如，避孕套和宫颈帽联合的两种屏障法）实现每年失败率< 1% 。使用屏障法必须辅以使用杀精剂。
13	对于男性：同意在治疗期间以及使用最后一次研究药物后至少3个月内保持禁欲状态或使用避孕套和额外的避孕措施（每年的失败率<1%)。仅当患者的首选和日常生活方式一致时，禁欲才能够接受。定期禁欲（例如，日历、排卵、症状体温或排卵后法），体外射精并非可接受的避孕措施。
14	进行任何研究相关操作之前能够且愿意提供书面知情同意并遵守研究方案，包括患者必须愿意且能够使用电子的患者自诉临床转归设备。

排除标准

1	既往3个年内曾罹患恶性肿瘤的患者需排除（除外已根治的皮肤基底细胞癌、内镜切除的早期胃肠道（GI）癌症、宫颈原位癌、或者任何认为对当前NSCLC的PFS和OS没有影响的已治愈癌症
2	所有可能影响口服药物吸收的胃肠道疾病，例如吸收不良综合征或重大肠切除手术后状态
3	肝脏疾病的特征为：通过两次连续测量确认ALT或AST>3 X ULN（伴发肝转移的患者为≥5XULN）或者分泌功能损伤（例如，高胆红素血症）或合成功能或其他失代偿性肝脏疾病，例如凝血障碍、肝性脑病、低蛋白血症以及食管静脉曲张导致的出血。或者急性病毒性或活动性自身免疫性、酒精性或其他类型的急性肝炎
4	各种既往治疗（例如放疗）导致出现国家癌症研究所不良事件通用术语标准（4.0版）定义的3级或更高级别的毒性（不包括脱发），这些毒性没有表现出任何改善，并认为会干扰目前的研究药物
5	器官移植病史
6	除本研究中药物外，与其他抗癌治疗联合给药。
7	基线QTc >470 ms的患者或有症状的心动过缓患者。
8	首次使用研究治疗前14天内以及alectinib或克唑替尼治疗过程中进行过特效/强效细胞色素P4503A抑制剂或诱导剂给药。
9	首次使用研究药物前14天内以及治疗过程中使用具有潜在QT间期延长效应的药物
10	对alectinib药物制剂中任何添加剂有过敏史（详见4.3.1.1）
11	对克唑替尼药物制剂中任何添加剂有过敏史（详见4.3.1.2）。

目标入组人数

国际多中心试验:总体286人，中国10人；

实际入组人数

登记人暂未填写该信息

4、试验分组

试验药

序号	名称	用法
1	alectinib胶囊	胶囊剂，规格：150mg,口服，每日两次，剂量：600mg/次，随餐服用。用药时程：持续用药至方案要求的时间（疾病进展，不可耐受的毒性、撤回知情同意或死亡）。

对照药

序号	名称	用法
1	克唑替尼胶囊	胶囊剂，规格：250mg, 口服，每日两次, 剂量：250mg/次，随餐或不随餐服用。用药时程：持续用药至方案要求的时间（疾病进展，不可耐受的毒性、撤回知情同意或死亡）。
2	克唑替尼胶囊	胶囊剂，规格：200mg, 口服，每日两次, 剂量：200mg/次，随餐或不随餐服用。用药时程：持续用药至方案要求的时间（疾病进展，不可耐受的毒性、撤回知情同意或死亡）。

5、终点指标

主要终点指标及评价时间

序号	指标	评价时间	终点指标选择
1	根据研究者评估的无进展生存期，评价和比较alectinib对比克唑替尼治疗初治的间变性淋巴瘤激酶-阳性晚期非小细胞肺癌患者的疗效	从随机化到患者首次发生疾病进展时	有效性指标

次要终点指标及评价时间

序号	指标	评价时间	终点指标选择
1	评估alectinib对比克唑替尼的安全性和耐受性	研究药物给药开始后直至最后一次给药后28天内发生的所有不良事件	安全性指标
2	评价和比较客观缓解率（ORR）和缓解持续时间（DOR	从随机日期到患者完全缓解和部分缓解时	有效性指标
3	根据IRC通过RECIST 1.1版和修订版神经肿瘤学评估（RANO）标准审查射线照片，评价和比较在CNS中的至进展时间，以及：评价在发生CNS转移且在基线时有可测量疾病的患者中的CNS客观缓解率（C-ORR）评价在实现CNS客观缓解的患者中的CNS缓解持续时间（C-DOR）根据累计发生率评价6、12、18和24个月时的CNS进展率（C-PR）	从随机化到患者首次发生神经系统疾病进展的时间；从随机化到记录中枢神经系统客观缓解时	有效性指标
4	评价和比较独立审核委员会(IRC)根据RECIST 1.1做出的无进展生存(PFS)评价结果	从随机化到患者首次发生疾病进展时	有效性指标
5	评价和比较OS	从从随机化直到任何原因导致死亡时	有效性指标
6	确定alectinib及其代谢产物的药代动力学特征	基线、第4周、第8周，之后每8周直至PD或死亡/PD之前退出研究, 每次给药前两小时,以及基线和第4周给药后第1、2、4、6、8小时。	有效性指标+安全性指标
7	患者自诉临床转归（PRO）目的	从随机化直到治疗结束后1年	有效性指标

6、数据安全监察委员会（DMC）：有

7、为受试者购买试验伤害保险：无

四、第一例受试者入组日期

登记人暂未填写该信息
2014-08-19国际

五、试验终止日期

登记人暂未填写该信息
登记人暂未填写该信息

六、研究者信息

1、主要研究者信息

姓名	张力	职称	教授
电话	020-87343458	Email	zhangli@sysucc.org.cn
邮政地址	广州市东风东路651号	邮编	510620
单位名称	中山大学附属肿瘤医院

2、各参加机构信息

序号	机构名称	主要研究者	国家	省（州）	城市
1	中山大学附属肿瘤医院	张力	中国	广东省	广州
2	上海市胸科医院	周彩存	中国	上海	上海
3	军事医学科学院附属医院	刘晓晴	中国	北京	北京
4	Calvary Mater Newcastle; Medical Oncology	Ina Nordma	澳大利亚	New South Wales	Waratah
5	QUEEN ELIZABETH HOSPITAL; MEDICAL ONCOLOGY	KEN　PITTMAN	澳大利亚	New South Wales	ADELAIDE

七、伦理委员会信息

序号	名称	审查结论	审查日期
1	中山大学附属肿瘤医院伦理委员会	同意	2015-09-09

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (13)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1947285, encodeId=a706194e28589, content=<a href='/topic/show?id=9c23228e32' target=_blank style='color:#2F92EE;'>#Alectinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2287, encryptionId=9c23228e32, topicName=Alectinib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Tue Jun 14 04:39:00 CST 2016, time=2016-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903903, encodeId=8add19039033a, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue May 31 10:39:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987515, encodeId=baaa198e515a2, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2323, encryptionId=540623233e, topicName=ALK阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed Nov 02 01:39:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915882, encodeId=432619158829e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Aug 30 14:39:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059524, encodeId=995320595242e, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon Apr 25 01:39:00 CST 2016, time=2016-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548495, encodeId=1b5915484957a, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Tue Dec 29 07:39:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594423, encodeId=385f159442361, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Dec 29 07:39:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49710, encodeId=208c49e10cf, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Sun Dec 27 22:52:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49686, encodeId=b3804968640, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sun Dec 27 21:53:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49513, encodeId=14ff49513ce, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 19:02:00 CST 2015, time=2015-12-27, status=1, ipAttribution=)]
2016-06-14 12498b08m90暂无昵称

#Alectinib#

28 0
[GetPortalCommentsPageByObjectIdResponse(id=1947285, encodeId=a706194e28589, content=<a href='/topic/show?id=9c23228e32' target=_blank style='color:#2F92EE;'>#Alectinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2287, encryptionId=9c23228e32, topicName=Alectinib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Tue Jun 14 04:39:00 CST 2016, time=2016-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903903, encodeId=8add19039033a, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue May 31 10:39:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987515, encodeId=baaa198e515a2, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2323, encryptionId=540623233e, topicName=ALK阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed Nov 02 01:39:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915882, encodeId=432619158829e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Aug 30 14:39:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059524, encodeId=995320595242e, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon Apr 25 01:39:00 CST 2016, time=2016-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548495, encodeId=1b5915484957a, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Tue Dec 29 07:39:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594423, encodeId=385f159442361, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Dec 29 07:39:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49710, encodeId=208c49e10cf, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Sun Dec 27 22:52:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49686, encodeId=b3804968640, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sun Dec 27 21:53:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49513, encodeId=14ff49513ce, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 19:02:00 CST 2015, time=2015-12-27, status=1, ipAttribution=)]
2016-05-31 luoxiaog

#多中心#

33 0
[GetPortalCommentsPageByObjectIdResponse(id=1947285, encodeId=a706194e28589, content=<a href='/topic/show?id=9c23228e32' target=_blank style='color:#2F92EE;'>#Alectinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2287, encryptionId=9c23228e32, topicName=Alectinib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Tue Jun 14 04:39:00 CST 2016, time=2016-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903903, encodeId=8add19039033a, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue May 31 10:39:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987515, encodeId=baaa198e515a2, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2323, encryptionId=540623233e, topicName=ALK阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed Nov 02 01:39:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915882, encodeId=432619158829e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Aug 30 14:39:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059524, encodeId=995320595242e, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon Apr 25 01:39:00 CST 2016, time=2016-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548495, encodeId=1b5915484957a, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Tue Dec 29 07:39:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594423, encodeId=385f159442361, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Dec 29 07:39:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49710, encodeId=208c49e10cf, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Sun Dec 27 22:52:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49686, encodeId=b3804968640, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sun Dec 27 21:53:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49513, encodeId=14ff49513ce, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 19:02:00 CST 2015, time=2015-12-27, status=1, ipAttribution=)]
2016-11-02 xjy02

#ALK阳性#

26 0
[GetPortalCommentsPageByObjectIdResponse(id=1947285, encodeId=a706194e28589, content=<a href='/topic/show?id=9c23228e32' target=_blank style='color:#2F92EE;'>#Alectinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2287, encryptionId=9c23228e32, topicName=Alectinib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Tue Jun 14 04:39:00 CST 2016, time=2016-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903903, encodeId=8add19039033a, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue May 31 10:39:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987515, encodeId=baaa198e515a2, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2323, encryptionId=540623233e, topicName=ALK阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed Nov 02 01:39:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915882, encodeId=432619158829e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Aug 30 14:39:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059524, encodeId=995320595242e, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon Apr 25 01:39:00 CST 2016, time=2016-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548495, encodeId=1b5915484957a, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Tue Dec 29 07:39:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594423, encodeId=385f159442361, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Dec 29 07:39:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49710, encodeId=208c49e10cf, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Sun Dec 27 22:52:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49686, encodeId=b3804968640, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sun Dec 27 21:53:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49513, encodeId=14ff49513ce, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 19:02:00 CST 2015, time=2015-12-27, status=1, ipAttribution=)]
2016-08-30 juliusluan78

#III#

31 0
[GetPortalCommentsPageByObjectIdResponse(id=1947285, encodeId=a706194e28589, content=<a href='/topic/show?id=9c23228e32' target=_blank style='color:#2F92EE;'>#Alectinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2287, encryptionId=9c23228e32, topicName=Alectinib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Tue Jun 14 04:39:00 CST 2016, time=2016-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903903, encodeId=8add19039033a, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue May 31 10:39:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987515, encodeId=baaa198e515a2, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2323, encryptionId=540623233e, topicName=ALK阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed Nov 02 01:39:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915882, encodeId=432619158829e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Aug 30 14:39:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059524, encodeId=995320595242e, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon Apr 25 01:39:00 CST 2016, time=2016-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548495, encodeId=1b5915484957a, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Tue Dec 29 07:39:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594423, encodeId=385f159442361, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Dec 29 07:39:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49710, encodeId=208c49e10cf, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Sun Dec 27 22:52:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49686, encodeId=b3804968640, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sun Dec 27 21:53:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49513, encodeId=14ff49513ce, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 19:02:00 CST 2015, time=2015-12-27, status=1, ipAttribution=)]
2016-04-25 lingaifan

#非小细胞#

36 0
[GetPortalCommentsPageByObjectIdResponse(id=1947285, encodeId=a706194e28589, content=<a href='/topic/show?id=9c23228e32' target=_blank style='color:#2F92EE;'>#Alectinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2287, encryptionId=9c23228e32, topicName=Alectinib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Tue Jun 14 04:39:00 CST 2016, time=2016-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903903, encodeId=8add19039033a, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue May 31 10:39:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987515, encodeId=baaa198e515a2, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2323, encryptionId=540623233e, topicName=ALK阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed Nov 02 01:39:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915882, encodeId=432619158829e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Aug 30 14:39:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059524, encodeId=995320595242e, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon Apr 25 01:39:00 CST 2016, time=2016-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548495, encodeId=1b5915484957a, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Tue Dec 29 07:39:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594423, encodeId=385f159442361, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Dec 29 07:39:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49710, encodeId=208c49e10cf, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Sun Dec 27 22:52:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49686, encodeId=b3804968640, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sun Dec 27 21:53:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49513, encodeId=14ff49513ce, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 19:02:00 CST 2015, time=2015-12-27, status=1, ipAttribution=)]
2015-12-29 ms1260584454294838

#招募#

31 0
[GetPortalCommentsPageByObjectIdResponse(id=1947285, encodeId=a706194e28589, content=<a href='/topic/show?id=9c23228e32' target=_blank style='color:#2F92EE;'>#Alectinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2287, encryptionId=9c23228e32, topicName=Alectinib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Tue Jun 14 04:39:00 CST 2016, time=2016-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903903, encodeId=8add19039033a, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue May 31 10:39:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987515, encodeId=baaa198e515a2, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2323, encryptionId=540623233e, topicName=ALK阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed Nov 02 01:39:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915882, encodeId=432619158829e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Aug 30 14:39:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059524, encodeId=995320595242e, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon Apr 25 01:39:00 CST 2016, time=2016-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548495, encodeId=1b5915484957a, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Tue Dec 29 07:39:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594423, encodeId=385f159442361, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Dec 29 07:39:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49710, encodeId=208c49e10cf, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Sun Dec 27 22:52:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49686, encodeId=b3804968640, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sun Dec 27 21:53:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49513, encodeId=14ff49513ce, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 19:02:00 CST 2015, time=2015-12-27, status=1, ipAttribution=)]
2015-12-29 智智灵药

#III期#

25 0
[GetPortalCommentsPageByObjectIdResponse(id=1947285, encodeId=a706194e28589, content=<a href='/topic/show?id=9c23228e32' target=_blank style='color:#2F92EE;'>#Alectinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2287, encryptionId=9c23228e32, topicName=Alectinib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Tue Jun 14 04:39:00 CST 2016, time=2016-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903903, encodeId=8add19039033a, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue May 31 10:39:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987515, encodeId=baaa198e515a2, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2323, encryptionId=540623233e, topicName=ALK阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed Nov 02 01:39:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915882, encodeId=432619158829e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Aug 30 14:39:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059524, encodeId=995320595242e, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon Apr 25 01:39:00 CST 2016, time=2016-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548495, encodeId=1b5915484957a, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Tue Dec 29 07:39:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594423, encodeId=385f159442361, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Dec 29 07:39:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49710, encodeId=208c49e10cf, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Sun Dec 27 22:52:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49686, encodeId=b3804968640, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sun Dec 27 21:53:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49513, encodeId=14ff49513ce, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 19:02:00 CST 2015, time=2015-12-27, status=1, ipAttribution=)]
2015-12-27 zhuzhuba1

牛

112 0
[GetPortalCommentsPageByObjectIdResponse(id=1947285, encodeId=a706194e28589, content=<a href='/topic/show?id=9c23228e32' target=_blank style='color:#2F92EE;'>#Alectinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2287, encryptionId=9c23228e32, topicName=Alectinib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Tue Jun 14 04:39:00 CST 2016, time=2016-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903903, encodeId=8add19039033a, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue May 31 10:39:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987515, encodeId=baaa198e515a2, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2323, encryptionId=540623233e, topicName=ALK阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed Nov 02 01:39:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915882, encodeId=432619158829e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Aug 30 14:39:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059524, encodeId=995320595242e, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon Apr 25 01:39:00 CST 2016, time=2016-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548495, encodeId=1b5915484957a, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Tue Dec 29 07:39:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594423, encodeId=385f159442361, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Dec 29 07:39:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49710, encodeId=208c49e10cf, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Sun Dec 27 22:52:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49686, encodeId=b3804968640, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sun Dec 27 21:53:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49513, encodeId=14ff49513ce, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 19:02:00 CST 2015, time=2015-12-27, status=1, ipAttribution=)]
2015-12-27 xyfg98

赞一个

127 0
[GetPortalCommentsPageByObjectIdResponse(id=1947285, encodeId=a706194e28589, content=<a href='/topic/show?id=9c23228e32' target=_blank style='color:#2F92EE;'>#Alectinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2287, encryptionId=9c23228e32, topicName=Alectinib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Tue Jun 14 04:39:00 CST 2016, time=2016-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903903, encodeId=8add19039033a, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue May 31 10:39:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987515, encodeId=baaa198e515a2, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2323, encryptionId=540623233e, topicName=ALK阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed Nov 02 01:39:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915882, encodeId=432619158829e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Aug 30 14:39:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059524, encodeId=995320595242e, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon Apr 25 01:39:00 CST 2016, time=2016-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548495, encodeId=1b5915484957a, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Tue Dec 29 07:39:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594423, encodeId=385f159442361, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Dec 29 07:39:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49710, encodeId=208c49e10cf, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Sun Dec 27 22:52:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49686, encodeId=b3804968640, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sun Dec 27 21:53:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49513, encodeId=14ff49513ce, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 19:02:00 CST 2015, time=2015-12-27, status=1, ipAttribution=)]
2015-12-27 wzf990214

有意思

101 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科

患者招募：一项比较ALECTINIB与克唑替尼用于治疗初治的ALK阳性晚期非小细胞肺癌的随机、多中心、III期、开放性研究

相关资讯

科室

工具

服务